Optimizing Surgical Management of Renal Hyperparathyroidism: Insights from a Single-Center Experience

Abstract

Aim: Renal hyperparathyroidism is one of the most common complications in patients with end-stage renal disease and is often resistant to medical treatment. Surgical treatment remains the only definitive option in cases resistant to pharmacological management.
Method: We retrospectively reviewed 480 patients who underwent parathyroid surgery between June 2020 and June 2025. Among them, 26 had renal hyperparathyroidism, and after applying exclusion criteria, 14 patients were included in the final analysis. Demographics, surgical strategies, perioperative biochemical data, complications, and follow-up outcomes were assessed.
Results: The study population consisted of 14 patients, including 10 males and 4 females. Patient age ranged from 23 to 61 years, dialysis duration ranged from 2 to 21 years, and length of hospital stay ranged from 3 to 28 days. Surgical approaches included subtotal parathyroidectomy (n=5), total parathyroidectomy (n=4), and purge parathyroidectomy (n=5). Preoperatively, parathyroid hormone levels were markedly elevated and showed a substantial postoperative decline, accompanied by improvements in serum calcium and phosphorus levels. Recurrent laryngeal nerve palsy and disease recurrence were observed in none of the patients with long-term follow-up. Postoperative hypocalcemia requiring intravenous calcium therapy was observed in 5 patients, three of whom had undergone purge parathyroidectomy and two total parathyroidectomy. 
Conclusion: In this retrospective series, parathyroidectomy was associated with marked biochemical improvement in patients with renal hyperparathyroidism refractory to medical management. Surgical approaches were applied according to patient-specific clinical characteristics and intraoperative findings.

Keywords

• End-stage renal disease
• purge parathyroidectomy
• secondary hyperparathyroidism
• renal hyperparathyroidism

Renal Hiperparatiroidizmde Cerrahi Tedavi Yaklaşımları: Tek Merkez Deneyimi

Abstract

Amaç: Sekonder ve tersiyer hiperparatiroidizm, son dönem böbrek yetmezliği olan hastalarda sık görülen ve çoğu zaman medikal tedaviye dirençli olan önemli komplikasyonlardır. Farmakolojik tedaviye yanıt alınamayan olgularda cerrahi tedavi tek seçenek olmaya devam etmektedir.
Yöntem: Haziran 2020 ve Haziran 2025 tarihleri arasında paratiroid cerrahisi uygulanan 480 hasta retrospektif olarak incelendi. Bu hastaların 26’sında renal hiperparatiroidizm mevcuttu. Dışlama kriterleri uygulandıktan sonra 14 hasta çalışmaya dahil edildi. Hastaların demografik özellikleri, uygulanan cerrahi yöntemler, perioperatif biyokimyasal veriler, komplikasyonlar ve takip sonuçları değerlendirildi.
Bulgular: Çalışmaya 10’u erkek, 4’ü kadın olmak üzere toplam 14 hasta dahil edildi. Hastaların yaşları 23–61 yıl arasında değişmekte olup, cerrahi öncesi diyaliz süreleri 2–21 yıl, hastanede yatış süreleri ise 3–28 gün arasında saptandı. Uygulanan cerrahi yaklaşımlar subtotal paratiroidektomi (n=5), total paratiroidektomi (n=4) ve purge paratiroidektomi (n=5) idi. Cerrahi öncesi paratiroid hormon düzeylerinin belirgin derecede yüksek olduğu ve cerrahi sonrası dönemde anlamlı bir düşüş gösterdiği, buna eşlik eden serum kalsiyum ve fosfor düzeylerinde düzelme izlendi. Uzun dönem takibi bulunan hastaların hiçbirinde rekürren laringeal sinir paralizisi veya hastalık nüksü saptanmadı. İntravenöz kalsiyum tedavisi gerektiren postoperatif hipokalsemi beş hastada gözlendi; bu hastaların üçüne purge paratiroidektomi, ikisine ise total paratiroidektomi uygulanmıştı.
Sonuç: Bu retrospektif seride, paratiroidektomi medikal tedaviye dirençli renal hiperparatiroidizm hastalarında belirgin biyokimyasal iyileşme ile ilişkili bulunmuştur. Cerrahi yaklaşımlar, hasta-özgü klinik özellikler ve intraoperatif bulgular doğrultusunda uygulanmıştır.

Keywords

• Purge paratiroidektomi
• renal hiperparatiroidizm
• son dönem böbrek yetmezliği
• sekonder hiperparatiroidizm

References

1. 1. Lorenz K, Bartsch DK, Sancho JJ, Guigard S, Triponez F. Surgical management of secondary hyperparathyroidism in chronic kidney disease—a consensus report of the European Society of Endocrine Surgeons. Langenbecks Arch Surg. 2015;400(8):907-927.
2. 2. Komaba H, Taniguchi M, Wada A, Iseki K, Tsubakihara Y, Fukagawa M. Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney International. 2015;88(2):350-359. doi: 10.1038/ki.2015.72.
3. 3. Hou J, Shan H, Zhang Y, et al. Network meta-analysis of surgical treatment for secondary hyperparathyroidism. American Journal of Otolaryngology. 2020;41(2):102370.
4. 4. Evenepoel P. Recovery versus persistence of disordered mineral metabolism in kidney transplant recipients. Seminars in Nephrology. 2013;33(2):191-203.
5. 5. Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) guideline update: What’s changed and why it matters. Kidney International. 2017;92(1):26-36.
6. 6. Schneider R, Slater EP, Karakas E, Bartsch DK, Schlosser K. Initial parathyroid surgery in 606 patients with renal hyperparathyroidism. World J Surg. 2012;36(2):318-326.
7. 7. Schlosser K, Bartsch DK, Diener MK, et al. Total parathyroidectomy with routine thymectomy and autotransplantation versus total parathyroidectomy alone for secondary hyperparathyroidism: Results of a nonconfirmatory multicenter prospective randomized controlled pilot trial. Annals of Surgery. 2016;264(5):745-753.
8. 8. Liang Y, Sun Y, Ren L, Qi XW, Li Y, Zhang F. Short-term efficacy of surgical treatment of secondary hyperparathyroidism. Eur Rev Med Pharmacol Sci. 2015;19(20):3904-3909.

9. 9. Phitayakorn R, McHenry CR. Incidence and location of ectopic abnormal parathyroid glands. The American Journal of Surgery. 2006;191(3):418-423.
10. 10. Chang LC, Liu SI, Liang TJ. Neck reoperation for recurrent or persistent renal hyperparathyroidism. World Journal of Surgery. 2023;47(11):2784-2791.
11. 11. Chen J, Zhou QY, Wang JD. Comparison between subtotal parathyroidectomy and total parathyroidectomy with autotransplantation for secondary hyperparathyroidism in patients with chronic renal failure: A meta-analysis. Horm Metab Res. 2015;47(09):643-651.
12. 12. Shan CX, Qiu NC, Zha SL, et al. A novel surgical strategy for secondary hyperparathyroidism: Purge parathyroidectomy. International Journal of Surgery. 2017;43:112-118. doi: 10.1016/j.ijsu.2017.05.062.
13. 13. Turan U. Clinical features of hypercalcemic crisis in primary hyperparathyroidism. Acta Endo (Buc). 2021;17(4):493-497. doi: 10.4183/aeb.20212.493.
14. 14. Fang L, Wu J, Luo J, et al. Changes in bone mineral density after total parathyroidectomy without autotransplantation in the end-stage renal disease patients with secondary hyperparathyroidism. BMC Nephrol. 2018;19(1):142. doi: 10.1186/s12882-018-0934-1.
15. 15. Uhlig K, Berns JS, Kestenbaum B, et al. KDOQI US Commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD–Mineral and Bone Disorder (CKD-MBD). American Journal of Kidney Diseases. 2010;55(5):773-799. doi: 10.1053/j.ajkd.2010.02.340.
16. 16. Rashid G, Bernheim J, Green J, Benchetrit S. Parathyroid hormone stimulates endothelial expression of atherosclerotic parameters through protein kinase pathways. American Journal of Physiology-Renal Physiology. 2007;292(4):F1215-F1218.
17. 17. Hamano T, Matsui I, Mikami S, et al. Fetuin-mineral complex reflects extraosseous calcification stress in CKD. Journal of the American Society of Nephrology. 2010;21(11):1998-2007. doi: 10.1681/ASN.2009090944.
18. 18. Jia X, Wang R, Zhang C, Cui M, Xu D. Long-term outcomes of total parathyroidectomy with or without autoimplantation for hyperparathyroidism in chronic kidney disease: A meta-analysis. Therapeutic Apheresis and Dialysis. 2015;19(5):477-485.
19. 19. Schlosser K, Zielke A, Rothmund M. Medical and surgical treatment for secondary and tertiary hyperparathyroidism. Scand J Surg. 2004;93(4):288-297.
20. 20. Tsai SH, Kan WC, Jhen RN, et al. Secondary hyperparathyroidism in chronic kidney disease: A narrative review focus on therapeutic strategy. Clin Med (Lond). 2024;24(5):100238. doi: 10.1016/j.clinme.2024.100238.
21. 21. Tang JA, Salapatas AM, Bonzelaar LB, Friedman M. Parathyroidectomy for the treatment of hyperparathyroidism: Thirty-day morbidity and mortality. The Laryngoscope. 2018;128(2):528-533. doi: 10.1002/lary.26604.
22. 22. Frequency of Ectopic and Supernumerary Intrathymic Parathyroid Glands in Patients with Renal Hyperparathyroidism: Analysis of 461 Patients Undergoing Initial Parathyroidectomy with Bilateral Cervical Thymectomy - Schneider - 2011 - World Journal of Surgery - Wiley Online Library. Accessed August 23, 2025. https://onlinelibrary.wiley.com/doi/10.1007/s00268-011-1079-6.
23. 23. Ishani A, Liu J, Wetmore JB, et al. Clinical outcomes after parathyroidectomy in a nationwide cohort of patients on hemodialysis. Clinical Journal of the American Society of Nephrology. 2015;10(1):90. doi: 10.2215/CJN.03520414.
24. 24. Okada M, Tominaga Y, Yamamoto T, Hiramitsu T, Narumi S, Watarai Y. Location frequency of missed parathyroid glands after parathyroidectomy in patients with persistent or recurrent secondary hyperparathyroidism. World Journal of Surgery. 2016;40(3):1.
25. 25. Conzo G, Della Pietra C, Tartaglia E, et al. Long-term function of parathyroid subcutaneous autoimplantation after presumed total parathyroidectomy in the treatment of secondary hyperparathyroidism. A clinical retrospective study. International Journal of Surgery. 2014;12:S165-S169. doi: 10.1016/j.ijsu.2014.05.019.
26. 26. Cinamon U, Levy D, Marom T. Is Primary Hyperparathyroidism a Risk factor for papillary thyroid cancer? An Exemplar Study and Literature Review. Int Arch Otorhinolaryngol. 2014;19(01):042-045. doi: 10.1055/s-0034-1396520.